Clinical trials
Trial starts, readouts, holds and designs.
Stories
-
New Phase 3 trials registered, week of October 26, 2026: 12 industry trials
Industry sponsors registered 12 Phase 3 trials on ClinicalTrials.gov in the week of October 26 to November 1, 2026. They plan to enroll 6,452 participants in all; the largest, Boehringer Ingelheim's Verducatib trial, plans to enroll 1,800.
-
AbbVie registers Phase 3 trial of upadacitinib in pediatric non-segmental vitiligo
The study will enroll approximately 154 participants aged 6 to <12 years and is expected to start on January 28, 2027. It is to evaluate the efficacy, safety, and tolerability of upadacitinib over 48 weeks of treatment followed by 112 weeks of continued blinded therapy.
-
Swedish Orphan Biovitrum registers Phase 3 trial of pegcetacoplan in kidney transplant recipients
The study, titled PRESERVE, plans to enroll 30 participants and has a planned start date of January 21, 2027. It aims to assess the efficacy and safety of pegcetacoplan for preventing recurrent C3G or primary IC-MPGN, with a planned primary completion date of January 17, 2031.
-
Amneal Pharmaceuticals registers Phase 3 trial of testosterone cypionate auto-injector
The Phase 3 study, recruiting 190 participants, was first posted on ClinicalTrials.gov on October 27, 2026, with primary completion projected for March 31, 2027. It aims to evaluate the safety, efficacy, and usability of a weekly subcutaneous testosterone cypionate auto-injector in adult males with hypogonadism.
-
Bayer posts results of Phase 3 finerenone trial in CKD with type 1 diabetes
The study, completed with 242 participants, compared finerenone plus standard of care to placebo in people with chronic kidney disease and type 1 diabetes. Results were first posted on ClinicalTrials.gov on October 27, 2026.
-
Jiangsu HengRui registers Phase III trial of HRS-6209 plus letrozole in advanced breast cancer
The study, led by Jiangsu HengRui Medicine Co., Ltd., plans to enroll 1050 participants and begin on November 20, 2026. It compares HRS-6209 plus letrozole with dalpciclib or palbociclib plus aromatase inhibitor in patients with advanced or metastatic breast cancer who have not received prior systemic treatment.
-
UNION trial shows 3-year event-free survival 91·3% vs 77·4%
In a prespecified interim analysis of 231 patients, the experimental group achieved a 3-year investigator-assessed event-free survival rate of 91·3% compared with 77·4% in the standard-of-care group (log-rank p=0·0029). Treatment-related serious adverse events occurred in 19% of experimental patients versus 13% of standard-of-care patients.
-
Pembrolizumab plus chemotherapy prolongs PFS versus monotherapy in high-PD-L1 NSCLC
In the PERSEE phase III trial, 321 patients with stage IV or unresectable stage III NSCLC and PD-L1 ≥50% were randomized to pembrolizumab alone or with platinum-based chemotherapy. Median progression-free survival was 16.1 months with combination versus 6.9 months with monotherapy (HR 0.56, 95% CI 0.43-0.74; P<0.001).
-
NSCLC, Lilly, and Pembrolizumab: the issue of October 19, 2026
The week of October 19 to 25, 2026: 48 briefs, 15 stories, led by NSCLC, Lilly, and Pembrolizumab.
-
PRABITAS trial shows 14-day trifluridine-tipiracil plus bevacizumab non-inferior to 28-day schedule
The authors reported that the 14-day schedule achieved a median overall survival of 11·3 months versus 10·3 months for the 28-day schedule, with a stratified hazard ratio of 0·93 (95% CI 0·80-1·08). Neutropenia grade 3 or worse was reduced by 25 percentage points (13% vs 39%) and anorexia grade 2 or worse by 11 percentage points (15% vs 26%).
-
Nivolumab plus ipilimumab shows significant OS benefit versus NIVO and chemotherapy
The authors reported a hazard ratio of 0.61 versus NIVO across all lines and 0.37 versus chemotherapy in first-line therapy, with 95% confidence intervals of 0.46-0.82 and 0.24-0.57 respectively. Grade 3/4 treatment-related adverse events occurred in 22% of NIVO+IPI patients versus 14% of NIVO patients, with no new safety concerns.
-
Lilly presents durable first-line activity of olomorasib in KRAS G12C-mutant NSCLC at ESMO 2026
Lilly reported that olomorasib plus pembrolizumab without chemotherapy achieved durable efficacy, with median progression-free survival not yet reached after a median follow-up of 20.7 months. In a separate rapid oral presentation, the combination with chemoimmunotherapy yielded a 62% investigator-assessed overall response rate and a median duration of response of 14.5 months.